O-0022 X-Pect Study Results: A Phase III Randomized Study of Perifosine Plus Capecitabine vs. Placebo Plus Capecitabine in Refractory mCRC Patients

Johanna Bendell; Thomas Ervin; Neil Senzer; Donald Richards; Irfan Firdaus; A. Craig Lockhart; Allen Cohn; Mansoor Saleh; Peter Sportelli; Lesa Gardner; Cathy Eng

doi:10.1016/S0923-7534(19)66486-0

$O-0022 X-Pect Study Results: A Phase III Randomized Study of Perifosine Plus Capecitabine vs. Placebo Plus Capecitabine in Refractory mCRC Patients$

Journal article

Peer reviewed

O-0022 X-Pect Study Results: A Phase III Randomized Study of Perifosine Plus Capecitabine vs. Placebo Plus Capecitabine in Refractory mCRC Patients

Johanna Bendell, Thomas Ervin, Neil Senzer, Donald Richards, Irfan Firdaus, A. Craig Lockhart, Allen Cohn, Mansoor Saleh, Peter Sportelli, Lesa Gardner, …

Annals of oncology, Vol.23, p.iv15

2012-06

DOI: https://doi.org/10.1016/S0923-7534(19)66486-0

Metrics

6 Record Views

Details

Title: O-0022 X-Pect Study Results: A Phase III Randomized Study of Perifosine Plus Capecitabine vs. Placebo Plus Capecitabine in Refractory mCRC Patients
Creators: Johanna Bendell
Thomas Ervin
Neil Senzer
Donald Richards
Irfan Firdaus
A. Craig Lockhart
Allen Cohn
Mansoor Saleh
Peter Sportelli
Lesa Gardner
Cathy Eng
Publication Details: Annals of oncology, Vol.23, p.iv15
Academic Unit: Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031598340902976